3D tissue models are revolutionizing diagnostics, drug development, and regenerative medicine fields.

Oxford Global’s protein degradation panel discussion brought together leading experts in the field to talk about bringing PROTACs to clinical trial endpoints.

Partnering with you to drive discovery

Target identification and validation forms the backbone of efforts to discover new drugs. Our expert panel discussed challenges and solutions in this field to drive safety and efficacy.

During Discovery Week 2021, Ian Churcher (Chief Scientific Officer at Amphista Therapeutics Limited) gave a fascinating presentation on recent advancements and novel approaches in protein degradation. This article provides a condensed overview of the key topics covered.

Cellesce develops bioprocessing systems for the expansion of organoids in significant volumes in a way that minimises handling time and maximises reproducibility, with the long term goal of positioning organoid technology as a cost effective model for early-stage drug discovery.

Dr Boris Adryan, Digital & Data Capability Building Lead at Merck Healthcare KGaA, teaches the company’s workforce the importance of data.

This Commentary piece looks at the means by which the global approval process for new medicines can be sped up through the controlled use of FAIR data. Key areas of focus include the sharing of healthcare data to bring the patient voice within the clinical setting.

This Commentary article revisits the development and implementation of mobile health data, exploring how initiatives such as the NHS track and trace system helped to mitigate the worst of the impact of the Covid-19 pandemic. Here, we consider the applications of mHealth data for present and future pandemic situations.

Key opinion leaders discuss the latest trends and challenges in laboratory automation and digitalization. Key insights include an explanation of Roche's 'Levers of Production' method, the challenges of legacy systems and the possibility of digitalization overload.

How are AI integration and the growing capabilities of machine learning impacting drug discovery and clinical trials?